Glaukos Co. (NYSE:GKOS) Shares Bought by Versor Investments LP

Versor Investments LP grew its position in shares of Glaukos Co. (NYSE:GKOS) by 55.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,442 shares of the medical instruments supplier’s stock after purchasing an additional 1,938 shares during the period. Versor Investments LP’s holdings in Glaukos were worth $816,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in GKOS. IFP Advisors Inc purchased a new stake in shares of Glaukos during the fourth quarter worth $43,000. Asset Planning Inc purchased a new stake in shares of Glaukos during the fourth quarter worth $90,000. Harvest Fund Management Co. Ltd increased its position in shares of Glaukos by 2,263.2% during the third quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock worth $117,000 after acquiring an additional 860 shares during the period. KBC Group NV increased its position in shares of Glaukos by 16.2% during the third quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock worth $188,000 after acquiring an additional 201 shares during the period. Finally, Congress Asset Management Co. purchased a new stake in shares of Glaukos during the fourth quarter worth $219,000. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Glaukos

In other Glaukos news, COO Joseph E. Gilliam sold 3,328 shares of the stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $149.85, for a total value of $498,700.80. Following the completion of the transaction, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at approximately $15,310,024.65. This trade represents a 3.15 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Gilbert H. Kliman sold 2,000 shares of the stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $144.01, for a total transaction of $288,020.00. Following the completion of the transaction, the director now directly owns 32,336 shares of the company’s stock, valued at approximately $4,656,707.36. This trade represents a 5.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 18,744 shares of company stock worth $2,792,151. Company insiders own 6.40% of the company’s stock.

Glaukos Price Performance

Shares of GKOS opened at $119.87 on Friday. Glaukos Co. has a fifty-two week low of $83.90 and a fifty-two week high of $163.71. The company has a market capitalization of $6.61 billion, a price-to-earnings ratio of -41.77 and a beta of 1.04. The firm has a 50-day simple moving average of $150.84 and a 200-day simple moving average of $139.31. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54.

Glaukos (NYSE:GKOS) last announced its earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The business had revenue of $105.50 million for the quarter, compared to analyst estimates of $100.72 million. On average, equities research analysts anticipate that Glaukos Co. will post -1.08 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on GKOS shares. Piper Sandler reaffirmed an “overweight” rating and set a $180.00 price objective (up previously from $140.00) on shares of Glaukos in a research report on Monday, January 27th. JPMorgan Chase & Co. increased their target price on Glaukos from $130.00 to $145.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Stifel Nicolaus increased their target price on Glaukos from $153.00 to $175.00 and gave the company a “buy” rating in a report on Tuesday, December 31st. Morgan Stanley lowered Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 target price on the stock. in a report on Monday, December 2nd. Finally, Citigroup raised Glaukos from a “neutral” rating to a “buy” rating and increased their target price for the company from $132.00 to $162.00 in a report on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Glaukos presently has an average rating of “Moderate Buy” and a consensus target price of $163.25.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.